Buy & Sell American Financial Group Inc (AFG) – American Financial Group Inc Price Today
Aura AI Summary
Key Stats
- $10.91BMarket Cap
- FinancialsSector
- -6.54%3M Drawdown
- $11.37BEnterprise Value
- 2.68%Dividend Yield
- 62 daysTypical Hold Time
American Financial Group Inc (AFG) is currently valued at a market capitalization of $10.91B, with an enterprise value of $11.37B. Over the past 52 weeks, American Financial Group Inc has traded between a low of $122.42 and a high of $148.71, highlighting its annual price range. Over the past three months, American Financial Group Inc has recorded a drawdown of -6.54%, reflecting recent price volatility. American Financial Group Inc offers a dividend yield of 2.68%, with the most recent dividend of $0.88 paid on 15 Apr 26. On average, investors hold American Financial Group Inc for approximately 62 days, indicating typical investor behavior on the platform.
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Most Recent News
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...

Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...

Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
